TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of R331333 (referred to as JNS024 Extended-Release (ER) or CG5503) compared with an active comparator (oxycodone Controlled Release (CR)) in Japanese and Korean patients with chronic, malignant, tumor-related cancer pain.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: oxycodone, Drug: pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone, Drug: pregabalin | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): A, B
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: R331333 (referred to as JNS024 ER or CG5503); Assigned to Arm(s): 001
C: Arm Label: Oxycodone Hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone Hydrochloride | Arm Label: Morphine Sulphate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulphate | Intervention Type: DRUG; Name: Oxycodone Hydrochloride; Assigned to Arm(s): Oxycodone Hydrochloride | Intervention Type: DRUG; Name: Morphine Sulphate; Assigned to Arm(s): Morphine Sulphate
D: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Oxycodone; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Fentanyl; Type: EXPERIMENTAL; Interventions: Drug: Fentanyl | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Fentanyl | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of R331333 (referred to as JNS024 Extended-Release (ER) or CG5503) compared with an active comparator (oxycodone Controlled Release (CR)) in Japanese and Korean patients with chronic, malignant, tumor-related cancer pain.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: R331333 (referred to as JNS024 ER or CG5503); Assigned to Arm(s): 001
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: oxycodone, Drug: pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone, Drug: pregabalin | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): A, B
C: Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets
D: Intervention Type: DRUG; Name: oxycodone fentanyl; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of Two Speed of Processing Modes to Prevent Cognitive Decline in Older Adults
Brief Summary: This is second-generation study based on results from ACTIVE (Advanced Cognitive Training for Independent and Vital Elderly). This four-arm study is known as IHAMS (the Iowa Healthy and Active Minds Study). The investigators will formally test from an intent-to-treat perspective for differences on the primary and secondary outcomes based on whether participants were randomized to the basic on-site speed of processing training (SOPT) group (G1), to the on-site basic SOPT plus subsequent booster-training group (G2), to the basic at-home SOPT group (G3), or to the basic attention-control group (G4). Basic training involves 10 hours of either the SOPT or attention-control training during the first 6 weeks of participation. Booster-training involves 4 additional hours of SOPT training at 11 months of participation.


Options:
A: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Lumosity Cognitive Training | Arm Label: Crossword Puzzles; Type: ACTIVE_COMPARATOR; Interventions: Other: Crossword Puzzles | Intervention Type: OTHER; Name: Lumosity Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Crossword Puzzles; Assigned to Arm(s): Crossword Puzzles
B: Arm Label: cognitive training; Type: EXPERIMENTAL; Interventions: Device: CogniFit Personal Coach® | Intervention Type: DEVICE; Name: CogniFit Personal Coach®; Assigned to Arm(s): cognitive training
C: Arm Label: Clinic-based SOPT basic training; Type: EXPERIMENTAL; Interventions: Behavioral: SOPT basic training | Arm Label: Home-based SOPT basic training; Type: EXPERIMENTAL; Interventions: Behavioral: SOPT basic training | Arm Label: Crossword Puzzles Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crossword Puzzles | Arm Label: SOPT basic and SOPT booster-training; Type: EXPERIMENTAL; Interventions: Behavioral: SOPT basic training, Behavioral: SOPT booster training | Intervention Type: BEHAVIORAL; Name: SOPT basic training; Assigned to Arm(s): Clinic-based SOPT basic training, Home-based SOPT basic training, SOPT basic and SOPT booster-training | Intervention Type: BEHAVIORAL; Name: Crossword Puzzles; Assigned to Arm(s): Crossword Puzzles Training | Intervention Type: BEHAVIORAL; Name: SOPT booster training; Assigned to Arm(s): SOPT basic and SOPT booster-training
D: Arm Label: Non-action video game training; Type: EXPERIMENTAL; Interventions: Other: Non-action video game training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Non-action video game training; Assigned to Arm(s): Non-action video game training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy
Brief Summary: Background:

Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clear defined and debatable. Therefore additional prophylactic pretreatments are needed.

Methods/Design:

Present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) a routine treatment without sarpogrelate group (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.

Discussion:

As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.


Options:
A: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3
C: Arm Label: sarpogrelate 300 mg per day; Type: EXPERIMENTAL; Interventions: Drug: sarpogrelate | Arm Label: No sarpogrelate medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: sarpogrelate; Assigned to Arm(s): sarpogrelate 300 mg per day
D: Intervention Type: DEVICE; Name: Renal Artery Stent with Protective Device/Drug; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Cholecalciferol on 24-hr ABPM and Vasoactive Hormones in Patients With Hypertension.
Brief Summary: High blood pressure is related to increased risk of cardiovascular disease and death, and accounts for approximately 8 mill deaths worldwide each year. Blood pressure exhibits a seasonal variation with a tendency to increase during winter months. Vitamin D deficiency is more common during months where UVB radiation from the sun is absent, and vitamin D has been associated with high blood pressure. This study will evaluate the effect of vitamin D replacement during winter months on blood pressure and vasoactive hormones in patients with high blood pressure.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 2
B: Arm Label: Cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Brief Summary: The objective of this study is to evaluate the safety and and hemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.


Options:
A: Arm Label: TachoSil®; Type: ACTIVE_COMPARATOR; Interventions: Biological: TachoSil® | Arm Label: Surgicel® Original; Type: ACTIVE_COMPARATOR; Interventions: Device: Surgicel® Original | Intervention Type: BIOLOGICAL; Name: TachoSil®; Assigned to Arm(s): TachoSil® | Intervention Type: DEVICE; Name: Surgicel® Original; Assigned to Arm(s): Surgicel® Original
B: Arm Label: EVARREST® Fibrin Sealant Patch; Type: EXPERIMENTAL; Interventions: Biological: EVARREST® Fibrin Sealant Patch | Arm Label: Standard of Care (SoC); Type: OTHER; Interventions: Other: Standard of Care (SoC) | Intervention Type: BIOLOGICAL; Name: EVARREST® Fibrin Sealant Patch; Assigned to Arm(s): EVARREST® Fibrin Sealant Patch | Intervention Type: OTHER; Name: Standard of Care (SoC); Assigned to Arm(s): Standard of Care (SoC)
C: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Drug: No tranexamic acid | Arm Label: Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: No tranexamic acid; Assigned to Arm(s): Standard Care | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Dose 1, Dose 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Brief Summary: The objective of this study is to evaluate the safety and and hemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.


Options:
A: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Infrahepatic inferior vena cava clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No infrahepatic inferior vena cava clamping | Intervention Type: PROCEDURE; Name: Infrahepatic inferior vena cava clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: No infrahepatic inferior vena cava clamping; Assigned to Arm(s): B
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Normovolemic Hemodilution (ANH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of care | Intervention Type: PROCEDURE; Name: Normovolemic Hemodilution (ANH); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard of care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WebQuit Online Smoking Cessation Study
Brief Summary: Would you like to quit smoking?

Seattle's Fred Hutchinson Cancer Research Center is launching a new study that may be able to help. Participants who enroll in this study will be randomly assigned by computer (like flipping a coin) to one of two online programs. The goal of this study is to learn which of these programs is the most effective at helping people stop smoking. Findings from this study will be used to help build more effective online smoking cessation programs in the future.

Participants in both of the smoking cessation programs used in this study will receive:

* Interactive tools for dealing more effectively with urges to smoke
* Step-by-step guides for quitting smoking
* Personalized plans for quitting and remaining smoke-free
* Electronic links for reaching one-on-one expert help for quitting

Participants will be asked to complete online questionnaires, including a brief three-month follow-up survey.

There is no cost for participating in this study.

To enroll in this study or for more information, please visit www.webquit.com.

This study is being conducted by Seattle's Fred Hutchinson Cancer Research Center (www.fhcrc.org), a world leader in advancing the prevention, diagnosis and treatment of cancer. The principal investigator for the WebQuit smoking cessation study is Dr. Jonathan Bricker, a faculty member at both the Hutchinson Center and at the University of Washington in Seattle.


Options:
A: Arm Label: WebQuit study group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit study group | Arm Label: WebQuit control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit control group | Intervention Type: BEHAVIORAL; Name: WebQuit study group; Assigned to Arm(s): WebQuit study group | Intervention Type: BEHAVIORAL; Name: WebQuit control group; Assigned to Arm(s): WebQuit control group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
C: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WebQuit Online Smoking Cessation Study
Brief Summary: Would you like to quit smoking?

Seattle's Fred Hutchinson Cancer Research Center is launching a new study that may be able to help. Participants who enroll in this study will be randomly assigned by computer (like flipping a coin) to one of two online programs. The goal of this study is to learn which of these programs is the most effective at helping people stop smoking. Findings from this study will be used to help build more effective online smoking cessation programs in the future.

Participants in both of the smoking cessation programs used in this study will receive:

* Interactive tools for dealing more effectively with urges to smoke
* Step-by-step guides for quitting smoking
* Personalized plans for quitting and remaining smoke-free
* Electronic links for reaching one-on-one expert help for quitting

Participants will be asked to complete online questionnaires, including a brief three-month follow-up survey.

There is no cost for participating in this study.

To enroll in this study or for more information, please visit www.webquit.com.

This study is being conducted by Seattle's Fred Hutchinson Cancer Research Center (www.fhcrc.org), a world leader in advancing the prevention, diagnosis and treatment of cancer. The principal investigator for the WebQuit smoking cessation study is Dr. Jonathan Bricker, a faculty member at both the Hutchinson Center and at the University of Washington in Seattle.


Options:
A: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Twelve Step Facilitation | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Cognitive Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Twelve Step Facilitation; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Integrated Cognitive Behavioral Treatment; Assigned to Arm(s): Arm 2
C: Arm Label: WebQuit study group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit study group | Arm Label: WebQuit control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit control group | Intervention Type: BEHAVIORAL; Name: WebQuit study group; Assigned to Arm(s): WebQuit study group | Intervention Type: BEHAVIORAL; Name: WebQuit control group; Assigned to Arm(s): WebQuit control group
D: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention

Answer: C